ACP5 and neoplasm: Consistent with the bone metastatic growth data, AMD3100 alone significantly decreased osteoclast occurrence in the KLF5KQ group but not in the KLF5KR group, as indicated by TRAP staining and quantitative analysis of TRAP + cells at the tumor-bone interface (Fig. 8d, f).